New MRI methods could unlock ARPKD treatment trials
NCT ID NCT07201025
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to develop better MRI-based tools to measure kidney disease progression in people with Autosomal Recessive Polycystic Kidney Disease (ARPKD), a serious genetic condition with no approved treatments. Researchers will enroll 45 ARPKD patients and 15 healthy volunteers aged 6 and older at two U.S. hospitals. Participants will undergo annual MRI scans and kidney function tests over three years to see if new imaging techniques can reliably track disease changes, which could help speed up future clinical trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.